Melanoma, Malignant Completed Phase 2 Trials for Ipilimumab (DB06186)

Also known as: Malignant Melanoma / [M]Malignant melanoma NOS / Melanoma / Melanoma malignant

IndicationStatusPhase
DBCOND0107071 (Melanoma, Malignant)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02272855A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaTreatment
NCT00135408A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideTreatment
NCT01480323A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2Treatment